Citigroup
TRDA icon

Citigroup’s Entrada Therapeutics TRDA Stock Holding History

Citigroup’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.2K Buy
4,853
+729
+18% +$8.35K ﹤0.01% 4448
2025
Q4 		$42.4K Buy
4,124
+2,075
+101% +$17.5K ﹤0.01% 4633
2025
Q3 		$11.9K Sell
2,049
-11,357
-85% -$66.4K ﹤0.01% 4965
2025
Q2 		$90.1K Sell
13,406
-5,180
-28% -$41.7K ﹤0.01% 4457
2025
Q1 		$168K Sell
18,586
-1,292
-6% -$16.1K ﹤0.01% 4298
2024
Q4 		$344K Buy
19,878
+1,896
+11% +$34.4K ﹤0.01% 4070
2024
Q3 		$287K Buy
17,982
+12,439
+224% +$196K ﹤0.01% 4102
2024
Q2 		$79K Sell
5,543
-50,744
-90% -$721K ﹤0.01% 4330
2024
Q1 		$798K Buy
56,287
+53,177
+1,710% +$752K ﹤0.01% 3209
2023
Q4 		$46.9K Buy
3,110
+3,079
+9,932% +$45.6K ﹤0.01% 4555
2023
Q3 		$490 Sell
31
-6,632
-100% -$104K ﹤0.01% 5212
2023
Q2 		$101K Sell
6,663
-55,360
-89% -$763K ﹤0.01% 4243
2023
Q1 		$899K Buy
62,023
+10,981
+22% +$147K ﹤0.01% 2644
2022
Q4 		$690K Buy
51,042
+49,459
+3,124% +$867K ﹤0.01% 2938
2022
Q3 		$25K Buy
1,583
+1,489
+1,584% +$18.9K ﹤0.01% 4661
2022
Q2 		$1K Sell
94
-319
-77% -$2.42K ﹤0.01% 6098
2022
Q1 		$4K Sell
413
-1,980
-83% -$21.2K ﹤0.01% 5913
2021
Q4 		$41K Buy
+2,393
New +$58K ﹤0.01% 5164

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's TRDA Position: Q1 2026 in Review

Citigroup increased its Entrada Therapeutics (TRDA) stake by 18% in Q1 2026, buying an estimated $8.35K and bringing the position to 4,853 shares worth $61.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4448.

Citigroup first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $899K in Q1 2023. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Citigroup held 4,853 shares of Entrada Therapeutics worth $61.2K as of Q1 2026.
  • Citigroup bought 729 Entrada Therapeutics shares in Q1 2026, an estimated $8.35K.
  • Entrada Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4448 holding.
  • Citigroup first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Citigroup's Entrada Therapeutics position peaked at $899K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.